Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
is there a reference?
Patients receiving compounded versions are extrapolating clinical evidence from STEP-1 (Wegovys pivotal trial), which showed average weight loss of 14.9% over 68 weeks at the 2.4 mg dose
Last month (May 2025), Novo announced that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) submission for an investigational once-daily oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease
Noom stands behind its program with a Taper-Off Guarantee offering a pathway off supposedly forever medications
